Professors

Name:Qin Ning

Professor of Immunology and Infectious Disease;
Director of Department of Infectious Disease;
Director of Institute of Infectious Diseases of Tongji Hospital.

Dr. Qin Ning is a Distinguished Professor & the chair of the Department of Infectious Diseases, and the Director of the Institute of Infectious Diseases in Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology. She has recently been appointed as the chief scientist of 973 Project in viral hepatitis and liver failure study from Ministry of Science and Technology of China.
Dr. Ning obtained her MD in 1985 and PhD in 1993 from Tongji Medical University, majored in infectious diseases. She then worked in the affiliated Tongji Hospital and specialized in infectious disease, and was appointed as an associate professor in 1997. From 1994 to 2000, she worked with Dr. Gary Levy as a post-doctoral fellow/research scientist in the Division of Gastroenterology and the Multiple Organ Transplant Program in the Toronto General Hospital and the University of Toronto, mainly towards to understanding the molecular mechanisms and pathogenesis of viral hepatitis. Dr. Ning returned to the Tongji Hospital in 2000 where she subsequently became a full professor. She assumed her current positions (Department chair) in August of 2006 and established the Institute of Infectious Disease in 2007.

Dr. Ning’s clinical care activities include infectious disease, clinical immunology, and hepatology with focus on hepatitis. She is currently a principal investigator of one national clinical trial study in viral hepatitis with Peg-IFN and co-investigator for several national and international clinical trials both in NA and IFNs. Her research interests are pathogenesis and molecular mechanisms of viral hepatitis (especially severe hepatitis, liver failure) and autoimmune liver disease, transplantation immunity and gene therapy, etc. She has been funded by the National Natural Science Foundation of China (NSFC) and has been awarded the National Science Fund for Distinguished Young Scholar, the Ministry of Education, and the Ministry of Science and Technology of China. She has published 6 book chapters and over 200 peer reviewed articles (together with publications in Chinese), including prestigious journals like J Clin Invest, J Biol Chem, J Immuol, J Virol, Human Gene Therapy, Liver International etc. She also served as editors and reviewers for Liver International, Human Gene Therapy, Journal of Gastroenterology and Hepatology, World Journal of Gastroenterology, the Chinese-German Journal of Clinical Oncology, Chinese Journal of Hepatology, and the Journal of Huazhong University of Science and Technology (English version) et al.

Dr. Ning is an international member of AASLD , a member of APASL Working Party on ACLF, and vice president of the Chinese Association for Controlling Infectious Disease, a member of Chinese Association for the Study of Liver, vice president of the Wuhan city’s Association for the Study of Infectious disease and the Hubei Provincial Society for study of Infectious Disease, etc.

Representative Publications
1. Q. Ning, D. Brown, J. Parodo, M. Cattral, R. Gorczynski, E. Cole, L.S. Fung, J.W. Ding, M.F. Liu, O. Rotstein, M.J. Phillips, and G.A. Levy. Ribavirin Inhibits Viral Induced Macrophage Production of TNF, IL-1, the Procoagulant fgl2 Prothrombinase and Preserves Th1 Cytokine Production but Inhibits Th2 Cytokine Response. The Journal of Immunology 1998; 160: 3487-3493.
2. Ning, Q., Liu, M.F. P. Kongkham, M.C. Lai, P.A. Marsden, J. Tseng, B. Pereira, M. Belyavskyi, J. Leibowitz, M.J. Phillips, and G.A. Levy. The Nucleocapsid Protein of Murine Hepatitis Virus Type 3 Induces Transcription of the Novel fgl2 Prothrombinase Gene. The Journal of Biological Chemistry; 1999, 274(15): 9930-9936.
3. Ning, Q. (corresponding author), L. Berger, X.P. Luo, W.M. Yan, F.L. Gong, J.W. Dennis, and G.A. Levy. STAT1 and STAT3 Splice-Form Activation Predicts Host Response in Mouse Hepatitis Virus Infection. The Journal of Medical Vioriology 2003 Mar;69(3):306-12
4. Ning, Q. (corresponding author), S. Lakatoo, M. Liu, Z.M. Wang, W.M. Yan, J. Leibowitz, M.J. Phillips, G.A. Levy. Induction of prothrombinase fgl2 by the nucleocapsid protein of virulent mouse hepatitis virus is dependent on host hepatic nuclear factor-4 ?. The Journal of Biology Chemistry; 2003;278;15541-15549。
5. Marsden PA*, Ning Q*, Fung LS, Luo XP, Chen Y, Mendicino M, Ghanekar A, Scott JA, Miller T, Chan C, Chan M, He W, Gorczynski RM, Grant DR, Clark DA, Phillips MJ, GA Levy. The Fgl2/fibroleukin prothrombinase contributes to immunologically-mediated thrombosis in experimental and human viral hepatitis. Jounal of Clinical Investigation,2003;112:58-66. ( * equal contribution).
6. Qin Ning (corresponding author), Yi Sun,Meifang Han, Li Zhang, Chuanglong Zhu, Weijie Zhang, Hui Guo, Weiming Yan, Jinwen Li, Feili Gong, Zhonghua Chen, Gary Levy, Xiaoping Luo. Role of fg12 prothrombinase/fibroleukin in experimental and human allograft rejection.2005, J of Immunology. 174: 7403-7411。
7. ChuanLong Zhu, Yi Sun, Xiaoping Luo, Weiming Yan, Dong Xi, Qin Ning (corresponding authour). Novel mfgl2 antisense plasmid inhibits mfgl2 expression and ameliorates MHV-3 induced fulminant hepatitis in Balb/cJ mice. 2006. Human Gene Therapy. 17(6):589-600. (Cover paper)。
8. Deng W, Shi M, Han M, Zhong J, Li Z, Li W, Hu Y, Yan L, Wang J, He Y, Tang H, Deubel V, Luo X, Ning Q (corresponding authour), Sun B. Negative regulation of virus-triggered IFN-beta signaling pathway by alternative splicing of TBK1. J Biol Chem. 2008 Dec 19;283(51):35590-7.
9. Han M, Yan W, Guo W, Xi D, Zhou Y, Li W, Gao S, Liu M, Levy G, Luo X, Ning Q (corresponding authour). Hepatitis B virus induced HFGl2 transcription is dependent on c-Ets-2 and MAPK signal pathway. J Biol Chem. 2008,283(11):32715-32729.
10. Zou Y, Chen T, Meifang Han, Wang H, Yan W, Song G, Wu Z, Wang X, Zhu C, Luo X, Qin Ning(corresponding authour). Increased killing of liver NK cells by Fas/Fas ligand and NKG2D/NKG2D ligand contributes to hepatocyte necrosis in virus-induced liver failure. The Journal of Immunology, 2010 Jan 1;184(1):466-475.
11. Wu Z, Yan W, Guo W, Chen T, Zou Y, Wang HW, Wang XJ, Qin Ning(corresponding authour). Telbivudine preserves T-helper 1 cytokine production and down regulates PD-L1 in a mouse model of viral hepatitis. J Viral Hepatitis. 2010. 01: 24-33
12.Sui Gao, Ming Wang, Huali Ye, Jianwen Guo, Dong Xi, ZhimoWang, Chuanlong Zhu, Weiming Yan, Xiaoping Luo, Qin Ning (corresponding author) .Dual interference of novel gene mfgl2 and mTNFR1 ameliorates murine hepatitis virus type 3-induced fulminant hepatitis in BALB/cJ mice. Hum Gene Ther. 2010 Aug;21(8):969-77. 2010.
13.Zeguang Wu, Meifang Han, Tao Chen, Weiming Yan and Qin Ning (corresponding author). Acute Liver Failure: Mechanisms of Immune-Mediated Liver Injury. Liver Int. 2010 Jul;30(6):782-94. Epub 2010 May 20.
14.Yanling Liu; Sanpeng Xu; Fei Xiao; Yan Xiong; Xiaojin Wang; Sui Gao; Weiming Yan; Qin Ning(corresponding author). The FGL2/fibroleukin prothrombinase is involved in alveolar macrophage activation in COPD through the MAPK pathway. Biochem Biophys Res Commun. 2010 May 28;396(2):555-61. Epub 2010 May 8.